Article

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.

Henry Ford Hospital, Detroit, Michigan, United States
Journal of the American College of Cardiology (Impact Factor: 15.34). 12/1995; 26(5):1133-9. DOI: 10.1016/0735-1097(95)00301-0
Source: PubMed

ABSTRACT This study was designed to evaluate the effect of pravastatin on progression of coronary atherosclerosis and ischemic events in patients with coronary artery disease and mild to moderate hyperlipidemia.
Few clinical trial data support the use of lipid-lowering therapy in patients with coronary artery disease and mild to moderate elevations in cholesterol levels.
Four hundred eight patients (mean age 57 years) with coronary artery disease and low density lipoprotein (LDL) cholesterol > or = 130 mg/dl (3.36 mmol/liter) but < 190 mg/dl ([4.91 mmol/liter]) despite diet were randomized in a 3-year study to receive pravastatin or placebo. Atherosclerosis progression was evaluated by quantitative coronary arteriography.
Baseline mean LDL cholesterol was 164 mg/dl (4.24 mmol/liter). Pravastatin decreased total and LDL cholesterol and triglyceride levels by 19%, 28% and 8%, respectively, and increased high density lipoprotein cholesterol by 7% (p < or = 0.001 vs. placebo for all lipid variables). Progression of atherosclerosis was reduced by 40% for minimal vessel diameter (p = 0.04), particularly in lesions < 50% stenosis at baseline. There was a consistent although not statistically significant effect on mean diameter and percent diameter stenosis. There were also fewer new lesions in those assigned pravastatin (p < or = 0.03). Myocardial infarction was reduced during active treatment (8 in the pravastatin group, 17 in the placebo group; log-rank test, p < or = 0.05; 60% risk reduction), with the benefit beginning to emerge after 1 year.
In patients with coronary artery disease and mild to moderate cholesterol elevations, pravastatin reduces progression of coronary atherosclerosis and myocardial infarction. The time course of event reduction increases the potential for a relatively rapid decrease in the clinical manifestations of coronary artery disease with lipid lowering.

0 Followers
 · 
159 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral arterial disease (PAD) in the context of this review refers to the presence of atherosclerotic disease in the arteries of the lower limbs. PAD is the third main site of atherosclerosis, after coronary heart disease and cerebrovascular disease. Intermittent claudication (IC) is the most known clinical manifestation of PAD, although most patients with this disorder are either asymptomatic of have atypical leg symptoms. Different drugs have been used in the past for the treatment of IC with limited results. As hypercholesterolemia is one of the main risk factors for atherosclerosis, cholesterol reduction has been shown to be effective in reducing cardiovascular morbidity and mortality. Statins are inhibitor of HMG CoA reductase, an enzyme essential in cholesterol synthesis. They effectively reduce total cholesterol and LDL cholesterol levels and are the most efficient drugs available today in the treatment of hypercholesterolemia. Several studies have demonstrated that statin administration in patients with PAD results in a decrease of progression and even regression in the growth of the atherosclerotic plaque. As patients with atherosclerosis of the lower limbs have frequently concurrent coronary or cerebrovascular disease, treatment of PAD with statins results in a simultaneous decrease in the incidence of coronary events and stroke. Statins have associated pleiotropic effects, including anti-inflammatory properties that contribute to their beneficial effects and to the reduction in cardiovascular death. In addition, several studies during the last years showed that statins improved pain-free walking distance, ankle brachial index and treadmill exercise time. As a result, current guidelines for cholesterol reduction in PAD patients adhered to the same indications as for other cardiovascular diseases and strongly recommend the administration of statins in these patients.
    International angiology: a journal of the International Union of Angiology 11/2014; · 1.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-obstructive coronary artery disease (CAD) is a frequent clinical condition and is associated with an increase in cardiovascular events. However, appropriate medical therapy for this population is not known. We investigated the association between statin use and risk of all-cause mortality and coronary revascularization in patients with non-obstructive CAD.
    Atherosclerosis 04/2015; 239(2). DOI:10.1016/j.atherosclerosis.2015.01.036 · 3.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hypertension (HT) and prehypertension (preHT) were independent predictors of cardiovascular diseases. Urinary albumin leakage is a manifestation of generalized vascular damage. B-type natriuretic peptide (BNP) is a vasoactive peptide secreted by left ventricle in response to myocytic stretch. We aimed to investigate relationship between microalbuminuria (MA) and BNP in untreated elevated blood pressures. Of 105 untreated prehypertensive subjects (53 men, 52 women), 100 hypertensive subjects (51 men, 49 women) and 57 normotensive subjects (32 men, 25 women) none had history of diabetes. Urine albumin excretion was measured by immunoradiometric assay in morning urine sample. The prevalence of MA was higher in hypertensive group than in prehypertensive group and in normotensive group (Hypertensive group; 33.9%, prehypertensive; 25.9%, normotensive; 10%). Subjects with HT had higher prevalence of microalbminuria; larger body mass index, higher levels of triglycerides, blood glucose and creatinin were more common in subjects with HT than in those with preHT. In hypertensive group; patients with microalbuminuria had higher systolic blood pressure (SBP), BNP, LVMI and lower eGFR as compared to those without MA. MA was significantly correlated with LVMI, BNP and SBP. In multivariate regression analysis, SBP (β: 0.361; P < 0.001), LVMII (β: 0.267; P = 0.011) and BNP (β: 0.284; P = 0.005) were independent variables associated with MA in hypertensives. In prehypertensive group; patients with microalbuminuria had higher SBP, BNP, LVMI and lower eGFR as compared to those without MA. MA was significantly correlated with LVMI, BNP and SBP. In multivariate regression analysis, SBP (β: 0.264; P = 0.002), LVMI (β: 0.293; P = 0.001) and BNP (β: 0.168; P = 0.045) were associated with MA in prehypertensives. In preHT and HT, SBP, BNP and LVMI are associated with MA. In the evaluation of increased blood pressures, in case of increased BNP and LVMI, MA should be investigated even in prehypertensive stages. The subjects with increased blood pressures should get medical treatment to prevent the effects on vascular structure and myocardium even in prehypertensive phase.
    International Journal of Clinical and Experimental Medicine 10/2014; 7(10):3420-3429. · 1.42 Impact Factor

Preview

Download
0 Downloads
Available from